PS4-4 COMPARISON OF EQ-5D AND SF-6D BASED COST-EFFECTIVENESS ANALYSIS OF HAEMODIALYSIS AND PERITONEAL DIALYSIS TREATMENTS

Tuesday, June 14, 2016
Exhibition Space (30 Euston Square)
Poster Board # PS4-4

Fan Yang, PhD1, Brenda Gannon, PhD1 and Nan Luo, PhD2, (1)Manchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom, (2)Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Purpose:

This study aimed to investigate whether the multi-attribute EuroQol-5D (EQ-5D) and Short Form-6D (SF-6D) utility instruments would lead to consistent cost-effectiveness outcomes when they are used to evaluate dialysis treatments for patients with end-stage renal disease (ESRD). 

Method(s):

A Markov model was constructed to compare haemodialysis (HD) and peritoneal dialysis (PD) for Singaporean ESRD patients with and without type 2 diabetes. Probabilistic sensitivity analysis (PSA) was used to determine cost-effectiveness by comparing the incremental cost-effectiveness ratio (ICER) based on costs incurred (in 2015 Singaporean dollars [S$]) and the quality-adjusted life years (QALYs) gained over a 10-year time horizon with a pre-determined maximum willingness-to-pay of S$60,000 per QALY. Cost and clinical inputs were estimated using local data and utility inputs were from Singaporean dialysis patients (HD: n=75; PD: n=75) interviewed using the 5-level EQ-5D (EQ-5D-5L) and Short Form-12 (SF-12) questionnaires.

EQ-5D scores were calculated using available EQ-5D-5L value sets (Canada, UK, and Japan), selected 3-level EQ-5D (EQ-5D-3L) value sets via crosswalk (Singapore, UK, Japan, and Thailand), and a crosswalk algorithm from SF-12 responses to UK EQ-5D-3L values. SF-6D scores were derived from SF-12 using a recommended algorithm.

Result(s):

For non-diabetic ESRD patients, the ICER of HD compared to PD was S$83,602 using SF-6D and ranged from 58,158 to 91,478 using EQ-5D scores. PSA showed that PD was more likely to be cost-effective using SF-6D and EQ-5D scores generated from SF-12, while HD was more likely to be preferable using EQ-5D scores generated from EQ-5D-5L.

For diabetic ESRD patients, the ICER was 82,365 using SF-6D and ranged from 67,984 to 96,110 using EQ-5D scores. PSA showed that two options were equally cost-effective using the Canada and UK EQ-5D-5L scores, while PD was more likely to be optimal using other scores. 

Conclusion(s):

We demonstrated that the choice of the EQ-5D and SF-6D instruments may affect the outcome of cost-effectiveness analysis, and so may be the case with the use of EQ-5D values from different sources or generated using different methods.